Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma
- 1 June 2009
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 113 (3) , 370-373
- https://doi.org/10.1016/j.ygyno.2008.12.021
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Functional characterization of PIK3CA as a breast cancer oncogene Review of: 1. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells 2. The oncogenic properties of mutant p110 alpha and p110 beta phosphatidylinositol 3-kinases in human mammary epithelial cellsBreast Cancer Online, 2006
- Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial CellsCancer Research, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- Her-2/neu Overexpression and Amplification in Uterine Papillary Serous CarcinomaJournal of Clinical Oncology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- Extended Surgical Staging for Uterine Papillary Serous Carcinoma: Survival Outcome of Locoregional (Stage I–III) DiseaseGynecologic Oncology, 2001
- Uterine Papillary Serous Carcinoma (UPSC): A Clinicopathologic Study of 30 CasesGynecologic Oncology, 1995